The Successor Promising Sector Attracting Attention in the Stock Market, Even After Significant Gains
Although the KOSPI showed a correction just short of the 8,000-point mark, there are projections that it could soon enter a full-fledged upward trend. In this scenario, CEO Lee Dongwoo has already selected three stocks that are expected to benefit the most.
■ SBS Biz CEO Lee Dongwoo, Praised as a 'Masterstroke' Among Individual Investors (Click)
CEO Lee Dongwoo provides a clear answer.
The most common question heard at all-time high levels is, 'Is it okay to enter now?' Historically, the average six-month return after the KOSPI breaks through its previous high has been +18%. Right now is the starting point."
■ Enter now to instantly check recommended stocks and tomorrow's strategy note! (Click)
The strategy he presents is simple.
Another turning point begins today. On the 28th and 29th (local time), the US FOMC will be held, and big tech earnings from companies such as Alphabet and Amazon will be released. Last Friday, Intel surged 23%, leading both the NASDAQ and S&P 500 to record all-time highs, and there is a high possibility that this momentum will continue when the domestic stock market opens today.
Since both major and minor issues that could impact the market are scheduled, it is recommended to seek advice from veteran experts and join in successful investing, rather than trading alone.
Recently hot stocks
Mobis Electronics, Keyang Electric, Cosmo Robotics, TPC Robotics, Heung-A Shipping
Hot Picks Today
Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "Those Who Hesitated at 3,000 Still Haven't Bought" 7 Trillion-Won Asset Manager Says "Opportunities Remain" [Investment Strategies of the Wealthy] ⑦
- Shin Ramyun Surpasses KRW 20 Trillion in Cumulative Sales, Marking a New Chapter in K-Ramen History
- Investment Warnings Surge... "Warning Light" Flashes as KOSPI Nears 8,000 Points
- 'Drugs to Prevent Aging' Enter Their First Target Year... First Patient Dosed in the US [New Path for Bio, Anti-Aging] ①
※ The content above is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.